Summary
Johnson & Johnson announced on September 30, 2014, a definitive agreement to acquire Alios BioPharma, Inc., a privately held biopharmaceutical company, for approximately $1.75 billion in cash. This strategic move signifies JNJ's commitment to expanding its pipeline in the infectious disease space, particularly in viral therapies. The acquisition targets Alios BioPharma's promising portfolio, notably the compound AL-8176. This orally administered antiviral therapy is currently in Phase 2 studies for treating respiratory syncytial virus (RSV) in infants. The addition of AL-8176 is expected to bolster JNJ's position in a significant therapeutic area with a substantial unmet medical need.
Key Highlights
- 1Johnson & Johnson to acquire Alios BioPharma for approximately $1.75 billion in cash.
- 2Acquisition targets Alios BioPharma's clinical-stage portfolio of therapies for viral diseases.
- 3Key asset includes AL-8176, an oral antiviral therapy in Phase 2 for infant RSV treatment.
- 4The deal is expected to close in the fourth quarter of 2014.
- 5The transaction is subject to customary closing conditions, including Hart-Scott-Rodino antitrust clearance.
Frequently Asked Questions
The acquisition of Alios BioPharma is driven by Johnson & Johnson's strategic interest in expanding its presence and pipeline in the infectious disease and viral therapy segments, particularly by acquiring promising clinical-stage assets like AL-8176.
AL-8176 is a key asset in the Alios BioPharma pipeline. It is an orally administered antiviral therapy currently in Phase 2 studies for the treatment of respiratory syncytial virus (RSV) in infants, a significant therapeutic area with a notable unmet medical need.
The transaction is anticipated to close during the fourth quarter of 2014, subject to regulatory approvals and other customary closing conditions.
Yes, the closing of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, in addition to other standard closing conditions.